title: Reply to S. Buti and S. Culine.
authors.forename: Yu-Ning
authors.initials: YN
authors.lastname: Wong
authors.forename: Elizabeth R
authors.initials: ER
authors.lastname: Plimack
authors.forename: Samuel
authors.initials: S
authors.lastname: Litwin
authors.forename: David
authors.initials: D
authors.lastname: Vaughn
authors.forename: James
authors.initials: J
authors.lastname: Lee
authors.forename: Wei
authors.initials: W
authors.lastname: Song
authors.forename: Gary R
authors.initials: GR
authors.lastname: Hudes
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017239:Paclitaxel